The PET images show, for the first time in human, glucagon expression in the liver (left) and GLP-1 expression in the pancreas (right) in a patient with type 2 diabetes
BPC-157 remains unapproved for human use, as large-scale clinical trials confirming its safety and efficacy are still absent, according to the Food and Drug Administration (FDA)
Its a choice that reflects a deliberate strategy to achieve a specific pharmacokinetic profile suitable for studying the slow, steady processes of metabolism
Our finding of high basal ERK level and a rapid increase in ERK activation with liraglutide that return to normal by 30 min is similar to reports by others in PSCs with other stimuli and in other cells with ERK activation
Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures
Graphical Abstract INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is a condition characterized by excessive fat build up in the liver, with a global prevalence of 25% [1,2]